We are in the process of restarting production for both TiO2 and functional additives in the first quarter of 2023, however we do not believe it is economically viable to continue TiO2 production
In light of these continuing challenging conditions, the Company has taken a number of recent actions, including: 1) implementing a $50 million cost reduction program, 2) closing a sale-leaseback transaction
Concerned by Venator's Alarming Long-Term Financial Underperformance, Massive Shareholder Value Destruction, Apparent Lack of Strategic Direction and Opaque Approach to Shareholder Engagement
Has Attempted to Engage
Companies Reporting Before The Bell
• Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.